JP2019515003A5 - - Google Patents

Download PDF

Info

Publication number
JP2019515003A5
JP2019515003A5 JP2018559369A JP2018559369A JP2019515003A5 JP 2019515003 A5 JP2019515003 A5 JP 2019515003A5 JP 2018559369 A JP2018559369 A JP 2018559369A JP 2018559369 A JP2018559369 A JP 2018559369A JP 2019515003 A5 JP2019515003 A5 JP 2019515003A5
Authority
JP
Japan
Prior art keywords
alkyl
substituents
halo
alkoxy
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018559369A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019515003A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/052701 external-priority patent/WO2017195113A1/en
Publication of JP2019515003A publication Critical patent/JP2019515003A/ja
Publication of JP2019515003A5 publication Critical patent/JP2019515003A5/ja
Pending legal-status Critical Current

Links

JP2018559369A 2016-05-11 2017-05-09 ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−3−イル酢酸誘導体 Pending JP2019515003A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662334718P 2016-05-11 2016-05-11
US62/334,718 2016-05-11
PCT/IB2017/052701 WO2017195113A1 (en) 2016-05-11 2017-05-09 Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

Publications (2)

Publication Number Publication Date
JP2019515003A JP2019515003A (ja) 2019-06-06
JP2019515003A5 true JP2019515003A5 (cg-RX-API-DMAC7.html) 2020-04-23

Family

ID=58745295

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018559369A Pending JP2019515003A (ja) 2016-05-11 2017-05-09 ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−3−イル酢酸誘導体

Country Status (4)

Country Link
US (1) US10407410B2 (cg-RX-API-DMAC7.html)
EP (1) EP3455215A1 (cg-RX-API-DMAC7.html)
JP (1) JP2019515003A (cg-RX-API-DMAC7.html)
WO (1) WO2017195113A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3455217A1 (en) * 2016-05-11 2019-03-20 ViiV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
US20200016136A1 (en) * 2017-01-03 2020-01-16 Viiv Healthcare Uk (No. 5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
TW201835068A (zh) * 2017-01-03 2018-10-01 英商Viiv醫療保健英國(No.5)有限公司 作為人類免疫缺乏病毒複製之抑制劑之吡啶-3-基乙酸衍生物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939545B2 (en) 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
EP2574610A1 (en) 2007-11-15 2013-04-03 Gilead Sciences, Inc. Inhibitors of human immonodeficiency virus replication
HRP20120328T2 (hr) 2007-11-15 2012-09-30 Gilead Sciences Inhibitori replikacije virusa humane imunodeficijencije
KR20100097156A (ko) 2007-11-16 2010-09-02 베링거 인겔하임 인터내셔날 게엠베하 사람 면역결핍 바이러스 복제의 억제제
CA2705338A1 (en) 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
US8338441B2 (en) * 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
CA2781780C (en) 2009-12-23 2015-02-17 Katholieke Universiteit Leuven Novel antiviral compounds
US8633200B2 (en) 2010-09-08 2014-01-21 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US8629276B2 (en) 2012-02-15 2014-01-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9034882B2 (en) * 2012-03-05 2015-05-19 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9580431B2 (en) 2013-03-13 2017-02-28 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
EP2970274B1 (en) 2013-03-14 2017-03-01 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
KR101821174B1 (ko) 2014-02-18 2018-01-23 트랜스오션 세드코 포렉스 벤쳐스 리미티드 해저 호스 교체를 위한 방법 및 장치
US9193720B2 (en) * 2014-02-20 2015-11-24 Bristol-Myers Squibb Company Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
AR105653A1 (es) 2015-08-11 2017-10-25 VIIV HEALTHCARE UK (Nº 5) LTD Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana
RU2018107928A (ru) * 2015-08-20 2019-09-20 ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД Производные пиридин-3-ил уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека
EP3455214A1 (en) * 2016-05-11 2019-03-20 ViiV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
EP3455217A1 (en) * 2016-05-11 2019-03-20 ViiV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

Similar Documents

Publication Publication Date Title
JP2016512558A5 (cg-RX-API-DMAC7.html)
JPWO2020085493A5 (cg-RX-API-DMAC7.html)
JP2017526748A5 (cg-RX-API-DMAC7.html)
JP2016512507A5 (cg-RX-API-DMAC7.html)
JP2016512511A5 (cg-RX-API-DMAC7.html)
JP2018522927A5 (cg-RX-API-DMAC7.html)
JP2018524390A5 (cg-RX-API-DMAC7.html)
HRP20191821T1 (hr) Antiproliferativni spojevi i načini njihove uporabe
JP2016528301A5 (cg-RX-API-DMAC7.html)
RU2017127135A (ru) Терапевтическое средство против рака желчных протоков
MX2015012760A (es) Composicion farmaceutica que comprende un activador de ampk y un agente serotonergico y metodos de uso de la misma.
JP2017504611A5 (cg-RX-API-DMAC7.html)
JP2015524841A5 (cg-RX-API-DMAC7.html)
JP2016535795A5 (cg-RX-API-DMAC7.html)
MX2024001849A (es) Antagonista del receptor del factor de liberacion de corticotropina 1 (crf1), formulaciones farmaceuticas y formas solidas del mismo para el tratamiento de hiperplasia suprarrenal congenita.
RU2017107715A (ru) Производные имидазо[1,2-a]пиридина для применения в качестве ингибиторов репликации вируса иммунодефицита человека
RU2018106498A (ru) Производные 5-(N-конденсированный трициклический арил-тетрагидроизохинолин-6-ил) пиридин-3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека
JP2016530213A5 (cg-RX-API-DMAC7.html)
JP2018522045A5 (cg-RX-API-DMAC7.html)
RU2017145649A (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ НА ОСНОВЕ АНТИТЕЛА К CD20 В СОЧЕТАНИИ С ИНГИБИТОРОМ BeI-2 И ИНГИБИТОРОМ MDM2
IL257240A (en) History of 5– (n– benzyl tetrahydroisoquinoline – 6 – il) Pyridine – 3 – il Acetic acid as inhibitors of human immunodeficiency virus replication
RU2016142611A (ru) Пролекарственные средства ингибиторов обратной транскриптазы вич
EA201990664A1 (ru) Производные 5-[2-(пиридин-2-иламино)-1,3-тиазол-5-ил]-2,3-дигидро-1h-изоиндол-1-она и их применение в качестве двойных ингибиторов фосфатидилинозитол-3-киназ дельта и гамма
JP2019515003A5 (cg-RX-API-DMAC7.html)
JP2016516692A5 (cg-RX-API-DMAC7.html)